BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cyto Pulse Sciences, Inc. Working With Walter Reed Army Institute of Research For Dengue Fever Vaccine Delivery Development


10/19/2005 5:09:16 PM

GLEN BURNIE, Md., Sept. 12 /PRNewswire/ -- The Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, has entered into an agreement with Cyto Pulse Sciences, Inc. (Cyto Pulse) of Glen Burnie, MD to develop a DNA vaccine delivery system against Dengue fever.

The agreement, signed in March 2005, is for a three-year project. WRAIR and Cyto Pulse Sciences desire to cooperate in research and development of methods for the administration of Flavivirus (Dengue) vaccines using a pulsed electric field delivery system. The Cyto Pulse Sciences vaccine delivery system uses an array of hundreds of small needles, each one coated with the DNA vaccine. An electric field allows the DNA to enter immune system cells in the skin, specifically the dendritic cells involved in immune system response.

Dengue fever or dengue hemorrhagic fever is a viral disease transmitted by mosquitoes. It is a devastating infection which is rapidly expanding in most tropical and subtropical areas of the world. The CDC calls it the most important arboviral (mosquito or tick-borne) disease of humans.

Work under a previous agreement with WRAIR demonstrated the protective efficacy of a prototype dengue-1 DNA vaccine using electric field-mediated DNA delivery. The new agreement continues that collaboration with testing of an improved, second generation DNA vaccine delivered by Cyto Pulse's new Easy Vax(TM) delivery system.

Cyto Pulse Sciences, Inc. is a medical device company developing and manufacturing systems used in monoclonal antibody production, gene therapy, vaccine production and delivering the new safe DNA/nucleic acid vaccines using its Easy Vax(TM) system. DNA/nucleic acid vaccines provide a total immunity similar to live virus vaccines and are much safer, but they must be delivered directly into the patient's immune system cells. Easy Vax(TM) solves the delivery problem. The company's technology provides the degree of safety, repeatability and efficiency required for commercial and clinical use.

The views expressed are those of the authors and should not be construed to represent the positions of the Department of the Army or Department of Defense.

Additional information on Cyto Pulse Sciences, Inc. is available at the company's website, http://www.cytopulse.com.

CONTACT: Cyto Pulse Science, Inc., +1-410-787-1890.

Cyto Pulse Science, Inc.

CONTACT: Tim Hurd of Cyto Pulse Science, Inc., +1-410-787-1890



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES